METASTATIC SOFT TISSUE SARCOMA

This study tests whether combining two drugs, cabozantinib and temozolomide, can help people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. About 96 adults with leiomyosarcoma or other similar sarcomas will take part. The goal is to see if the …

This study tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to the targeted therapy cabozantinib can shrink tumors better than cabozantinib alone in people with advanced soft tissue sarcoma. About 105 participants whose cancer has spread or cannot be remove…

This early-phase study tests several new drug combinations in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drugs can shrink tumors. About 352 adults with specific cancer types will participate…

This study tests a new combination of two drugs, lurbinectedin and doxorubicin, for people with advanced leiomyosarcoma, a rare soft tissue cancer. The first part finds a safe dose, and the second part compares the combination to lurbinectedin alone to see which works better. Abo…

This study tests whether adding the drug cabozantinib to a standard immunotherapy combination (ipilimumab and nivolumab) works better than immunotherapy alone for people with advanced soft tissue sarcoma. About 66 adults with specific sarcoma types that have spread or cannot be r…

This study tests a combination of two drugs, HDM201 and pazopanib, in people with advanced soft tissue sarcoma that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 47 adults whose tumors have a specific genetic feature…

This study tests whether adding two immunotherapy drugs (zalifrelimab or botensilimab plus balstilimab) to standard chemotherapy (doxorubicin) can keep advanced soft tissue sarcoma from growing longer than chemo alone. About 65 adults with sarcoma that has spread or cannot be rem…